2012•AIDSRequires access
No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients
Richa Singh, Neal Marshall, Colette Smith, Carl Reynolds, Ronan Breen, Sanjay Bhagani, Ian Cropley, Susan Hopkins, Leonie Swaden, Margaret Johnson, Marc Lipman
Open publisher page 8 citations
Abstract
Rifabutin has been substituted for rifampicin when treating tuberculosis (TB)/HIV coinfection. However, despite reports of anti-TB treatment failure and acquired rifamycin resistance, long-term clinical outcome data are lacking. Observational analyses performed in a UK TB/HIV cohort demonstrated no difference in severe adverse events, anti-TB treatment completion, relapse frequency or subsequent rifamycin resistance when rifampicin and rifabutin were compared, using different combinations of antiretroviral therapy. Our data support the wider use of rifabutin in TB/HIV coinfection.